Lung Cancer Cells Hijack Immune System for Growth, Offering Fresh Treatment Pathways
Lung adenocarcinoma, the most prevalent form of lung cancer, remains a leading cause of cancer-related deaths worldwide. While advancements in treatment have been made, the disease often develops resistance to therapies, creating an urgent need for innovative approaches. Researchers at the Salk Institute have uncovered a previously unknown mechanism by which lung cancer cells exploit a specific type of immune cell, macrophages, to fuel their growth, and proliferation. This discovery, published in Cancer Discovery on January 25, 2024, offers a promising new avenue for therapeutic intervention, potentially enhancing the effectiveness of existing treatments when combined with commonly used cholesterol-lowering drugs.
The study focuses on lung adenocarcinomas driven by mutations in the epidermal growth factor receptor (EGFR) gene. EGFR plays a crucial role in cell growth and division, and mutations can lead to uncontrolled proliferation. Modern immunotherapies, which harness the body’s own immune system to fight cancer, have shown limited success against EGFR-driven lung adenocarcinoma. This resistance, coupled with the eventual development of resistance to targeted EGFR inhibitors, has spurred scientists to investigate the intricate interactions within the tumor microenvironment – the complex ecosystem surrounding the cancer cells – to identify vulnerabilities.
The research team found that these cancer cells don’t grow in isolation. They actively recruit and manipulate lung-resident macrophages, specialized immune cells normally responsible for clearing debris and maintaining the delicate balance of lipids – fats – within the lungs’ alveoli, the tiny air sacs essential for oxygen exchange. Instead of performing their protective function, these macrophages are hijacked and reprogrammed by the tumor cells to supply them with vital nutrients, particularly cholesterol, effectively becoming fuel providers for cancer growth. This process isn’t a one-time event. the tumor cells stimulate macrophage proliferation, creating a self-sustaining cycle of nutrient supply and tumor expansion.
The Role of Macrophages and Alveoli in Lung Health
To understand the significance of this discovery, it’s essential to appreciate the normal function of macrophages within the lungs. The lungs rely on millions of alveoli, tiny balloon-like structures, to facilitate the exchange of oxygen and carbon dioxide. As the American Lung Association explains, these alveoli require a lipid-rich environment to function optimally. Macrophages play a critical role in maintaining this environment, ensuring a healthy balance of lipids, including cholesterol, which are vital for cell function, energy storage, and vitamin absorption.
However, when lung cancer cells enter the picture, they disrupt this delicate balance. The tumor cells exploit the macrophages’ natural ability to regulate lipid metabolism, turning it against the lungs themselves. The researchers discovered that the cancer cells secrete a growth factor called GM-CSF (granulocyte macrophage colony-stimulating factor). This GM-CSF triggers a specific gene within the macrophages, PPARγ (peroxisome proliferator-activated receptor gamma), initiating a metabolic reprogramming that leads to increased lipid secretion. Essentially, the cancer cells are forcing the macrophages to produce more cholesterol, which the tumor cells then consume to fuel their growth and further activate the EGFR signaling pathway.
A Novel Feedback Loop Driving Cancer Progression
The study revealed a particularly concerning aspect of this interaction: a positive feedback loop. Not only are the tumor cells reprogramming the macrophages to provide them with nutrients, but they are also instigating a metabolic state within themselves that further enhances their growth. “Not only were the tumor cells metabolically reprogramming the macrophages – they were also instigating a feedback loop that encouraged an optimal metabolic state in the tumor cells themselves,” explained co-corresponding author Katerina Politi, scientific director of the Center for Thoracic Cancers at Yale Cancer Center and professor of pathology at Yale School of Medicine.
This discovery suggests that disrupting this feedback loop could be a powerful strategy for slowing down EGFR-driven cancer growth. Researchers are now investigating exactly how the delivery of lipids, like cholesterol, to tumor cells powers the EGFR oncogenic pathway – the process by which the mutated EGFR gene drives cancer development. “Our results reveal new therapeutic possibilities for immunotherapy-resistant EGFR-driven lung adenocarcinomas,” stated co-corresponding author Christian Metallo, professor and holder of the Daniel and Martina Lewis Chair at Salk. “We have identified a key metabolic relationship between macrophages and alveoli that is exploited by tumor cells to support the cancer’s metabolic demands – now we just have to disrupt that exploitation.”
Potential Therapeutic Implications: Combining Existing Drugs
The Salk Institute team proposes a promising therapeutic approach: combining existing treatments with readily available medications. They suggest that EGFR inhibitors, which target the mutated EGFR protein, may be more effective when paired with statins, a class of drugs commonly prescribed to lower cholesterol levels. By limiting the availability of cholesterol, statins could potentially starve the tumor cells of a crucial nutrient source, hindering their growth and proliferation.
the researchers recommend exploring the use of PPARγ inhibitors, which would directly disrupt the macrophage hijacking process. Combining PPARγ inhibitors with statins and EGFR inhibitors could create a multi-pronged attack on the cancer, targeting both the tumor cells and the supporting immune cells. Clinical trials are needed to evaluate the efficacy and safety of this combined approach.
The implications of this research extend beyond EGFR-driven lung adenocarcinoma. The researchers are investigating whether similar immunological hijacking mechanisms occur in other types of cancer and within different tumor microenvironments. If this proves to be the case, the findings could pave the way for new therapeutic strategies applicable to a broader range of cancers. According to the EGFR Cancer Resisters Group, the EGFR mutation is present in roughly 15 percent of people with lung cancer in the United States, though this number is significantly higher – between 35 and 50 percent – in individuals of Eastern Asian descent.
Understanding EGFR Mutations and Lung Cancer
The EGFR gene provides instructions for making a protein called epidermal growth factor receptor, which is found on the surface of cells. This receptor helps cells grow and divide. Mutations in the EGFR gene can cause the receptor to become overactive, leading to uncontrolled cell growth and cancer. The American Lung Association notes that EGFR-positive lung cancer represents about 10-15% of all lung cancers in the U.S. And is most often found in the adenocarcinoma subtype.
While targeted therapies, such as EGFR inhibitors, have shown initial success in treating EGFR-mutated lung cancers, many patients eventually develop resistance to these drugs. This resistance underscores the need for a deeper understanding of the complex interactions within the tumor microenvironment and the development of novel therapeutic strategies to overcome this challenge.
The research team, including Ziyan Xu, Ramya Kuna, Kacie Traina, Anna-Maria Globig, and Reuben Shaw of Salk; Thekla Cordes of Technishe Universität Braunschweig in Germany; Elizabeth Kwong and Sandra Leibel of UC San Diego School of Medicine and Sanford Consortium for Regenerative Medicine; Matthew Nobari and George Cheng of UC San Diego Department of Medicine; and Camila Robles-Otei?za, Deborah Ayeni, Stellar Levy, and Robert Homer of Yale School of Medicine, are continuing to investigate these mechanisms. Their work is supported by grants from the National Institutes of Health (R01CA230275, R01CA195720, R35CA220538, R01CA234245, R01CA216101S1), the Yale Cancer Biology Training Program (T32CA193200-01A1), Mark Foundation for Cancer Research, Yale University Interdisciplinary Immunology Training Grant (T32AI-007019), NOMIS Foundation, Waitt Foundation, Chapman Foundation, Helmsley Charitable Trust, and Helmsley Center for Genomic Medicine.
The next step will be to translate these findings into clinical trials to assess the effectiveness of combining EGFR inhibitors, statins, and PPARγ inhibitors in patients with EGFR-driven lung adenocarcinoma. Further research is also needed to determine whether similar mechanisms are at play in other cancer types, potentially opening up new avenues for treatment across a wider spectrum of malignancies.
This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. We see essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Do you have questions about lung cancer research or treatment options? Share your thoughts and experiences in the comments below. Please also share this article with anyone who might find it helpful.
Keep reading